Post‐acute sequelae of COVID ‐19 in cancer patients: Two cohorts in UK and Hong Kong

Abstract

Background: Limited research exists on the risks and spectrum of complications in post‐acute phase of COVID‐19 in cancer patients. This study aimed to evaluate the post‐acute effects of COVID‐19 on different types of morbidities among cancer patients across two regions with different healthcare systems and dominant variants of COVID‐19. Materials and Methods: Cancer patients with COVID‐19 from the UK Biobank (UKB, n = 2230; March 16, 2020 to May 31, 2021; pre‐Omicron‐variants dominant) and electronic medical records in Hong Kong (HK cohort, n = 22,335; April 1, 2020 to October 31, 2022; Omicron‐variant dominant) were included. Each COVID‐19 case was randomly matched with up to 10 non‐COVID‐19 cancer patients based on age and sex. Follow‐up lasted until 31 August 2021 for UKB and 23 January 2023 for HK. Inverse probability treatment weighting balanced cohort characteristics. Cox regression evaluated the association of COVID‐19 with morbidities occurred 30 days post‐infection. Results: Cancer patients with COVID‐19 consistently showed significantly higher risk of major cardiovascular diseases (CVDs) [UKB: hazard ratio [HR] 1.8 (95% CI 1.3, 2.5); HK: HR 1.4 (95% CI 1.1, 1.8)], CVD death [UKB: HR 4.3 (95% CI 2.9, 6.2); HK: HR 1.7 (95% CI 1.3, 2.4)], and all‐cause mortality [UKB: HR 4.7 (95% CI 4.0, 5.5); HK: HR 1.6 (95% CI 1.5, 1.7)] in both cohorts despite the difference in dominant variants. Cancer patients at advanced ages or severely infected had higher all‐cause mortality risk. However, associations between COVID‐19 and CVDs became insignificant for fully vaccinated patients. Conclusion: COVID‐19 infection is associated with increased risks of CVDs and mortality in cancer patients. Fully vaccination may reduce the post‐acute effects of COVID‐19 on CVDs. This information may guide effective pre‐emptive measures to reduce COVID‐19‐related morbidities and mortality in cancer patients.

Publication DOI: https://doi.org/10.1002/cam4.70134
Divisions: College of Health & Life Sciences > Aston Pharmacy School
Funding Information: The Health Bureau and University Grants Committee's Collaborative Research Fund, both under the Government of the Hong Kong Special Administrative Region, supported the study. The grant numbers are COVID19F01 and C7154-20GF. Despite their financial suppor
Additional Information: Copyright © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Uncontrolled Keywords: cancers,long‐term effect,CVDs,COVID‐19
Publication ISSN: 2045-7634
Last Modified: 01 Apr 2025 07:11
Date Deposited: 10 Dec 2024 18:40
Full Text Link:
Related URLs: https://onlinel ... 1002/cam4.70134 (Publisher URL)
http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2024-12
Published Online Date: 2024-12-07
Accepted Date: 2024-08-09
Authors: Wan, Eric Yuk Fai
Lee, Shing Fung
Zhou, Jiayi
Yan, Vincent Ka Chun
Lai, Francisco Tsz Tsun
Chui, Celine Sze Ling
Li, Xue
Wong, Carlos King Ho
Chan, Esther Wai Yin
Wong, Ian Chi Kei (ORCID Profile 0000-0001-8242-0014)

Download

[img]

Version: Published Version

License: Creative Commons Attribution

| Preview

Export / Share Citation


Statistics

Additional statistics for this record